A multinational pharmaceutical company headquartered in Basel, Switzerland, Novartis researches, develops, manufactures, and distributes prescription medicines globally. The company's portfolio spans oncology, cardiovascular, immunology, neuroscience, and hematology, with marketed therapies including Entresto for heart failure, Cosentyx for autoimmune conditions, Kisqali for breast cancer, Tasigna for chronic myeloid leukemia, and Jakavi for myelofibrosis. The company also markets Xolair for allergic asthma, Zolgensma for spinal muscular atrophy, and Pluvicto for metastatic prostate cancer, among other specialty and primary care medications.
Novartis operates across multiple therapeutic areas, with particular strength in specialty medicines targeting oncology, cardiovascular disease, and rare genetic disorders. The company maintains collaboration agreements with external partners, including Alnylam Pharmaceuticals for the development and commercialization of Leqvio, a cholesterol-reducing therapy.
The company operates at significant scale with approximately 75,000 full-time employees and maintains a market capitalization of approximately $317 billion. Novartis is listed on the New York Stock Exchange and pays a dividend yield of approximately 2.82 percent. Its operations span Switzerland, the United States, and international markets, positioning it as a global pharmaceutical manufacturer with diverse geographic revenue streams.
No 10-K filings found.